Abstract:
BACKGROUND:South Korea is unique in that it leads global markets in R&D as well as production of biosimilar products and was the first market into which some biosimilar products were introduced. We analyzed the time trend of market penetration and simulated saved spending by biosimilars in South Korea. METHODS:We pulled Korean National Health Insurance claims data from January 2012-December 2018 for second-generation biologics, including infliximab, rituximab, and trastuzumab, and examined the time trends of expenditure, utilization in defined daily dose, and price. We also assessed market penetration by biosimilars and simulated expenditure savings gained due to their introduction. We comparatively examined time trends and spending savings during the same period for selected small-molecule generic drugs to understand any specifics limited to biosimilars for time trends of market share and quantity-standardized prices. RESULTS:The market share for infliximab biosimilar plateaued at over 30%, which is smaller than the market penetration of esomeprazole (over 60%), a small-molecule comparator. Despite a shorter observation period, rituximab and trastuzumab biosimilars also showed larger utilization rates (12.89% and 13.93%, respectively) than infliximab (9.05%) in their second year after market entry. Infliximab was associated with approximately US $82-114 million expenditure savings over 6 years after its biosimilar entry to the market. Rituximab and trastuzumab biosimilars each also resulted in reduction in total spending by approximately US $9-14 million, in less than 2 years. CONCLUSION:Biosimilars captured the market rapidly, despite a heterogeneous uptake rate by product in South Korea. However, expansion of biosimilar use in the market and consequent expenditure savings need to be supported by pre-emptive policy measures to encourage price competition and boost utilization.
journal_name
Appl Health Econ Health Policyjournal_title
Applied health economics and health policyauthors
Lee HJ,Han E,Kim Hdoi
10.1007/s40258-019-00547-7subject
Has Abstractpub_date
2020-08-01 00:00:00pages
557-566issue
4eissn
1175-5652issn
1179-1896pii
10.1007/s40258-019-00547-7journal_volume
18pub_type
杂志文章abstract:CONTEXT:The in-hospital costs of extracorporeal membrane oxygenation (ECMO) have not been well established. OBJECTIVE:To evaluate the in-hospital costs of ECMO technology in both US and non-US settings for all patient types. DATA SOURCES:Systematic review of English-language articles, using the PubMed, Embase, Web of...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-015-0170-9
更新日期:2015-08-01 00:00:00
abstract:BACKGROUND:The Xpert® MTB/RIF (Xpert) test has been shown to be effective and cost-effective for diagnosing tuberculosis (TB) under conditions with high HIV prevalence and HIV-TB co-infection but less is known about Xpert's cost in low HIV prevalence settings. Cambodia, a country with low HIV prevalence (0.7%), high TB...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0397-3
更新日期:2018-08-01 00:00:00
abstract::The first objective of this paper is to expound the particular challenge posed by the occurrence of inconsistency in the expression of preferences by mental health patients to both economists and policy makers. Since this difficulty cannot be resolved, the second aim of the paper is to identify agents who may be count...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-019-00479-2
更新日期:2020-04-01 00:00:00
abstract:BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-015-0183-4
更新日期:2015-08-01 00:00:00
abstract:OBJECTIVES:The aim of this study was to review all published economic evaluations of guideline-based care for chronic wounds and to assess how useful these studies are for decision making in health services. METHODS:Embase, PubMed, Scopus, Health Technology Assessment (HTA) and National Health Service Economic Evaluat...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0403-9
更新日期:2018-10-01 00:00:00
abstract:OBJECTIVE:To develop a statistical model generating utility estimates for prostate cancer specific health states, using preference weights derived from the perspectives of prostate cancer patients, men at risk for prostate cancer, and society. METHODS:Utility estimate values were calculated using standard gamble (SG) ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0282-x
更新日期:2017-06-01 00:00:00
abstract:BACKGROUND:Low back pain (LBP) is a major health problem, having a substantial effect on peoples' quality of life and placing a significant economic burden on healthcare systems and, more broadly, societies. Many interventions to alleviate LBP are available but their cost effectiveness is unclear. OBJECTIVES:To identi...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-016-0268-8
更新日期:2017-04-01 00:00:00
abstract::A routine part of the process for developing National Institute for Health and Care Excellence (NICE) medical technologies guidance is a submission of clinical and economic evidence by the technology manufacturer. The Birmingham and Brunel Consortium External Assessment Centre (EAC; a consortium of the University of B...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-014-0117-6
更新日期:2014-10-01 00:00:00
abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is the second most common cancer in Taiwan. For males in Taiwan, it is the most dangerous cancer, with both the highest incidence and mortality rate. OBJECTIVE:To determine cancer-related medical care costs for long-term survivors of HCC. METHODS:The estimation of the lifetim...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200806010-00005
更新日期:2008-01-01 00:00:00
abstract::The debate surrounding whether the findings of efficacy studies are applicable to real-world treatment situations is ongoing. The issue of lack of applicability due to a lack of clinical heterogeneity could be addressed by employing less restrictive inclusion criteria. Given that health economic assessments based on c...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11590150-000000000-00000
更新日期:2011-05-01 00:00:00
abstract:BACKGROUND:Immunization rates for human papillomavirus (HPV) infections remain low among teenagers despite strong evidence of the effectiveness of vaccines. Physician recommendations of the vaccine are far from universal. Several states have enacted policies that mandate HPV vaccination or distribute educational materi...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-016-0225-6
更新日期:2016-06-01 00:00:00
abstract::The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256149
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Limited empirical evidence exists regarding the effect of price changes on hospital behavior and, ultimately, the quality of care. Additionally, an overview of the results of prior literature is lacking. OBJECTIVE:This study aims to provide a synthesis of existing research concerning the relationship betwee...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-020-00577-6
更新日期:2020-10-01 00:00:00
abstract::The aim of the review is to establish whether, on the basis of previous published evidence, current accepted guidance for health economic evaluation needs to be adapted to evaluate healthcare based on use of genetic information. Online literature search strategies were designed (using PubMed and the NHS Economic Evalu...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.2165/00148365-200605010-00004
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. OBJECTIVE:To estimate the cost effectivene...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11535520-000000000-00000
更新日期:2010-01-01 00:00:00
abstract:BACKGROUND:The Patient Protection and Affordable Care Act instituted pay-for-performance programs, including Hospital Value-Based Purchasing (HVBP), designed to encourage hospital quality and efficiency. OBJECTIVE AND METHOD:While these programs have been evaluated with respect to their implications for care quality a...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-017-0357-3
更新日期:2018-02-01 00:00:00
abstract::This article reviews the concept of costing, and how cost data have been considered and reported in recent multinational economic evaluations. It appears that current practice frequently does not comply with microeconomic foundations and standards for good practice. A number of studies fail to indicate the year of cos...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:Updated treatment guidelines for atrial fibrillation (AF) have been released by the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a current shortfall in the prescription of anticoagulants to patients with AF for stroke prevention. OBJECTIVE:To design a budget impact model...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-015-0180-7
更新日期:2015-10-01 00:00:00
abstract:BACKGROUND:Cost-effectiveness analyses (CEAs) have been performed for oral non-disease-altering osteoarthritis (OA) treatments for well over a decade. During that period the methods for performing these analyses have evolved as pharmacoeconomic methods have advanced, new treatments have been introduced, and the knowled...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-013-0061-x
更新日期:2013-12-01 00:00:00
abstract::The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute for Health and Care Excellence, through its Medical Technologies Evaluat...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-018-0447-x
更新日期:2019-02-01 00:00:00
abstract::Payment incentives to both consumers and providers have significant consequences for the equity and efficiency of a healthcare system, and have recently come to the fore in health policy reforms. This review first discusses the economic rationale for the apparent international convergence toward payment systems with m...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200403010-00009
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:Decision makers within the Calgary Health Region adopted and applied programme budgeting and marginal analysis (PBMA) for priority-setting activity across major service portfolios within the Region. METHODS:Seventeen in-depth qualitative interviews were conducted with senior managers and clinicians to gain ...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/00148365-200403030-00005
更新日期:2004-01-01 00:00:00
abstract::The mandatory nature of recommendations made by the National Institute for Health and Clinical Excellence (NICE) in the UK has highlighted inherent difficulties in the process of disinvestment in existing technologies to fund NICE-approved technologies. A lack of evidence on candidate technologies means that the proce...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/BF03256137
更新日期:2009-01-01 00:00:00
abstract::Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/BF03261872
更新日期:2012-11-01 00:00:00
abstract:OBJECTIVES:To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies. METHODS:Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (D...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-018-0440-4
更新日期:2019-06-01 00:00:00
abstract:BACKGROUND:Costs of chronic wound care are significant, but systematic reviews of cost-effectiveness studies regarding guideline-based or strategic interventions are scarce. OBJECTIVES:Our objectives were to assess/compare the cost effectiveness of new interventions/systems designed to improve the prevention/treatment...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-014-0094-9
更新日期:2014-08-01 00:00:00
abstract::Central line-associated bloodstream infections (CLABSIs) are primary, laboratory confirmed bloodstream infections in patients with a central line within 48 h of symptom onset. Catheter-related bloodstream infection (CRBSI) is a more specific term used when the cause of infection has been confirmed by catheter tip cult...
journal_title:Applied health economics and health policy
pub_type: 杂志文章,评审
doi:10.1007/s40258-020-00602-8
更新日期:2020-08-05 00:00:00
abstract:BACKGROUND:Osteoporosis is recognized as a serious health condition in developed as well as developing countries. There are no accurate estimates of the extent of the burden of osteoporosis in New Zealand. The purpose of this study was to estimate the economic burden of osteoporosis in New Zealand using data from inter...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.2165/11531500-000000000-00000
更新日期:2011-03-01 00:00:00
abstract:BACKGROUND:There is obscurity regarding how US hospitals determine patients' charges. Whether insurance status influences a patient's hospital charge has not been explored. OBJECTIVE:The objective of this study was to determine whether hospitals charge patients differently based on their insurance status. METHODS:Thi...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-017-0308-z
更新日期:2017-06-01 00:00:00
abstract::This paper examines the use of propensity score matching in economic analyses of observational data. Several excellent papers have previously reviewed practical aspects of propensity score estimation and other aspects of the propensity score literature. The purpose of this paper is to compare the conceptual foundation...
journal_title:Applied health economics and health policy
pub_type: 杂志文章
doi:10.1007/s40258-013-0075-4
更新日期:2014-02-01 00:00:00